Compliance assessment of dexamethasone suppression testing.
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Specimen should be collected between 8-10 a.m.
Serum separator tube, lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
After separation from cells: Ambient: Unacceptable; Refrigerated: 1 week; Frozen: 6 months
Adults baseline: Less than 50 ng/dL
8:00 AM draw following 1 mg dexamethasone between 11:00 pm and 12:00 am the previous evening: 140 - 295 ng/dL
8:00 AM draw following 8 mg dexamethasone (4 x 2 mg doses) between 11:00 pm and 12:00 am the previous evening: 1600 - 2850 ng/dL
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
|2003249||Dexamethasone, Serum or Plasma, LC-MS/MS||14062-4|